BIOMARIN PHARMACEUTICAL INC Proceeds from Sale of Intangible Assets
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Proceeds from Sale of Intangible Assets of $25.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2020-02-27
- BIOMARIN PHARMACEUTICAL INC proceeds from sale of intangible assets for the quarter ending 2019-12-31 was $10.00M, a 66.67% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC proceeds from sale of intangible assets for the quarter ending 2019-09-30 was $15.00M.
- BIOMARIN PHARMACEUTICAL INC proceeds from sale of intangible assets for the quarter ending 2018-12-31 was $30.00M, a 76.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC proceeds from sale of intangible assets for the quarter ending 2018-09-30 was $0.00.
- BIOMARIN PHARMACEUTICAL INC proceeds from sale of intangible assets for fiscal 2019 was $25.00M, a 50.00% decline from fiscal 2018.
- BIOMARIN PHARMACEUTICAL INC proceeds from sale of intangible assets for fiscal 2018 was $50.00M, a 60.00% decline from fiscal 2017.
- BIOMARIN PHARMACEUTICAL INC proceeds from sale of intangible assets for fiscal 2017 was $125.00M.
- BIOMARIN PHARMACEUTICAL INC proceeds from sale of intangible assets for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
| Period end | Proceeds from Sale of Intangible Assets 1 month | Proceeds from Sale of Intangible Assets 3 month | Proceeds from Sale of Intangible Assets 6 month | Proceeds from Sale of Intangible Assets 9 month | Proceeds from Sale of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $10.00M derived: 10-K 12 month − 10-Q/A 9 month · filed 2020-02-27 | $25.00M derived: sum of 2 quarters · filed 2020-02-27 | $25.00M 10-K · filed 2020-02-27 | ||
| 2019-09-30 | $15.00M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $15.00M 10-Q/A · filed 2019-11-04 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-02 | ||||
| 2018-12-31 | $30.00M derived: 10-K 12 month − 10-Q/A 9 month · filed 2020-02-27 | $30.00M derived: sum of 2 quarters · filed 2020-02-27 | $50.00M 10-K · filed 2020-02-27 | ||
| 2018-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $20.00M 10-Q/A · filed 2019-11-04 | |||
| 2018-06-30 | $20.00M 10-Q · filed 2019-08-02 | ||||
| 2017-12-31 | $125.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $125.00M derived: sum of 2 quarters · filed 2020-02-27 | $125.00M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $0.00 10-Q · filed 2018-10-26 | |||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-03 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | $410.00M 10-K · filed 2018-02-26 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $67.50M 10-K · filed 2017-02-27 | |||
| 2014-09-30 | $67.50M 10-Q · filed 2015-11-02 | ||||
| 2014-07-31 | $67.50M 10-Q · filed 2014-10-28 | ||||
| 2013-09-30 | $0.00 10-Q · filed 2014-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |